Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisitions (Details Textual)

v3.21.1
Note 4 - Acquisitions (Details Textual) - Changzhou Eminence Biotechnology [Member] - USD ($)
$ in Thousands
5 Months Ended
Oct. 20, 2020
Mar. 31, 2021
Mar. 31, 2021
Business Acquisition, Percentage of Voting Interests Acquired 47.60%    
Business Combination, Consideration Transferred, Total $ 9,800    
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value $ 8,985 $ 8,985 $ 8,985
Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Initial Investment   9,800 9,800
Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Loans Made   800 800
Goodwill, Purchase Accounting Adjustments   $ (963)  
Developed Technology Rights [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 13 years    
Customer Relationships [Member]      
Finite-Lived Intangible Asset, Useful Life (Year) 10 years    
Minimum [Member]      
Variable Interest Entity, Financial or Other Support Expected Amount     6,000
Maximum [Member]      
Variable Interest Entity, Financial or Other Support Expected Amount     $ 12,000